title: Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study.
abstract: BACKGROUND
  Retinal vein occlusion (RVO) is a common cause of unilateral visual loss. Evidence based treatment recommendations for patients with RVO cannot be made because of the lack of adequate clinical trials. To compare the efficacy and safety of aspirin and of a low molecular weight heparin, parnaparin, in the treatment of RVO.
  
  
  METHODS
  In a multicenter, randomized, double blind, controlled trial eligible patients with a delay between symptoms onset and objective diagnosis of less than 15 days were randomized to aspirin 100 mg/day for 3 months or to a fixed daily dose of parnaparin, 12.800 IU for 7 days followed by 6.400 IU for a total of 3 months. Primary end-point of the study was the incidence of functional worsening of the eye with RVO at 6 months, as assessed by fluorescein angiography, visual acuity, and visual field. Study end-points were adjudicated by an independent committee.
  
  
  RESULTS
  Sixty-seven patients were enrolled in the study and 58 of them (28 treated with parnaparin, 30 with aspirin) were evaluable for the analysis. Baseline characteristics were well balanced between groups. Functional worsening was adjudicated in 20.7% of patients treated with parnaparin and in 59.4% of patients treated with ASA (p=0.002). Recurrent RVO was diagnosed in 3 patients, all treated with ASA (p=n.s.). Bleeding rates were similar between the two groups.
  
  
  CONCLUSIONS
  Parnaparin appears to be more effective than aspirin in preventing functional worsening in patients with RVO. The results of this study need to be confirmed in a larger clinical trial.
authors.affiliation: University of Insubria, Varese, Italy. agewal@yahoo.com
authors.forename: Walter
authors.initials: W
authors.lastname: Ageno
authors.forename: Roberto
authors.initials: R
authors.lastname: Cattaneo
authors.forename: Elisa
authors.initials: E
authors.lastname: Manfredi
authors.forename: Paolo
authors.initials: P
authors.lastname: Chelazzi
authors.forename: Luigi
authors.initials: L
authors.lastname: Venco
authors.forename: Angelo
authors.initials: A
authors.lastname: Ghirarduzzi
authors.forename: Luca
authors.initials: L
authors.lastname: Cimino
authors.forename: Esmeralda
authors.initials: E
authors.lastname: Filippucci
authors.forename: Angela Luisa
authors.initials: AL
authors.lastname: Ricci
authors.forename: Donatella
authors.initials: D
authors.lastname: Romanelli
authors.forename: Carlo
authors.initials: C
authors.lastname: Incorvaia
authors.forename: Sergio
authors.initials: S
authors.lastname: D'Angelo
authors.forename: Fiamma
authors.initials: F
authors.lastname: Campana
authors.forename: Francesco
authors.initials: F
authors.lastname: Molfino
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Scannapieco
authors.forename: Flavia
authors.initials: F
authors.lastname: Rubbi
authors.forename: Davide
authors.initials: D
authors.lastname: Imberti
mesh_terms: D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006470:Hemorrhage; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010975:Platelet Aggregation Inhibitors; C080945:parnaparin; D001241:Aspirin